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Evaluation of Intratumoral HER-2 Heterogeneity by Fluorescence 
In Situ Hybridization in Invasive Breast Cancer: A Single 
Institution Study
This study aimed to determine the incidence and characteristics of HER-2 gene 
heterogeneity in invasive breast cancer in a single institution. Included were 971 cases of 
primary invasive breast cancer diagnosed between 2008 and 2010. Fluorescence in situ 
hybridization (FISH) image files were retrospectively reviewed and HER-2 gene 
heterogeneity was defined as more than 5% but less than 50% of analyzed invasive tumor 
cells with a HER-2/Chr17 ratio higher than 2.2, according to the College of American 
Pathologists guidelines. HER-2 gene heterogeneity was identified in 24 (2.5%) cases. The 
mean proportion of invasive tumor cells with a HER-2/chromosome 17 ratio higher than 
2.2 was 11.6% (range: 5%-25%). Of 24 cases, HER-2 gene status was not amplified in 8, 
showed borderline amplification in 2, and amplification in 14. All HER-2 amplification 
cases were low-grade. In conclusion, HER-2 gene heterogeneity of invasive breast cancer is 
identified in routine FISH examination. This may affect the results of HER-2 gene 
amplification status in FISH studies.
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INTRODUCTION
HER-2 is an oncogene that is overexpressed and/or amplified 
in about one-third of breast cancer cases (1, 2). It is associated 
with tumor aggressiveness such as high tumor grade, lymph node 
metastasis, and brain metastasis (3-7). More importantly, HER-2 
is a biomarker for targeted immunotherapy such as with trastu-
zumab (8-10). Therefore, the proper evaluation of HER-2 gene 
status is important for breast cancer therapy. In clinical practice, 
the standard method to examine HER-2 gene status is immuno-
histochemistry (IHC) or fluorescence in situ hybridization (FISH) 
(11-13). However, breast cancer is typically a heterogeneous tu-
mor with intratumoral heterogeneity in not only histologic fea-
tures, but also genetic features (14, 15). The incidence of HER-2 
gene heterogeneity in invasive breast cancer is 1.3%-54% (16-21). 
However, the incidence of HER-2 gene heterogeneity in invasive 
breast cancer in Korea has not been studied. The purpose of this 
study was to investigate the incidence and characteristics of HER-
2 gene heterogeneity in invasive breast cancer in routine FISH 
examination.
MATERIALS AND METHODS
Patients 
This study included 972 cases of primary invasive breast cancer 
diagnosed between January 2008 and December 2010. We ret-
rospectively reviewed image files from FISH studies for the HER-
2 gene that had at least three images (range 3-10) per case. Clin-
icopathologic parameters such as age at initial diagnosis, histo-
logic type, histologic grade, estrogen receptor status, progester-
one receptor status, and HER-2 IHC results were obtained from 
pathology reports. The histological grade was assessed using the 
Nottingham grading system (22). HER-2 staining was analyzed 
according to the American Society of Clinical Oncology (ASCO)/ 
College of American Pathologists (CAP) guidelines using the 
following categories: 0 = no immunostaining; 1+ = weak incom-
plete membranous staining, less than 10% of tumor cells; 2+ = 
complete membranous staining, either uniform or weak in at 
least 10% of tumor cells; and 3+ = uniform intense membranous 
staining in at least 30% of tumor cells (23).
FISH analysis
Before FISH analysis, invasive tumors were examined on hema-
toxylin-eosin stained slides. FISH was subsequently performed 
on the tested tumor. FISH was performed using a PathVysion 
HER-2 DNA Probe Kit (Vysis, Downers Grove, IL, USA) accord-
ing to the manufacturer’s instructions. HER-2 gene copy num-
ber on the slides was evaluated using an epifluorescence micro-
scope (Olympus, Tokyo, Japan). At least 60 tumor cell nuclei in 
three separate regions were investigated for HER-2 and chromo-
Lee S, et al. • Intratumoral Heterogeneity of HER-2
1002  http://jkms.org DOI: 10.3346/jkms.2011.26.8.1001
some 17 signals. HER-2 gene amplification was determined ac-
cording to the ASCO/CAP guidelines. An absolute HER-2 gene 
copy number lower than 4 or a HER-2 gene/chromosome 17 copy 
number ratio (HER-2/Chr17 ratio, or amplification index [AI]) 
less than 1.8 was considered HER-2 negative. An absolute HER-
2 copy number between 4 and 6 or a HER-2/Chr17 ratio between 
1.8 and 2.2 was considered HER-2 equivocal. An absolute HER-2 
copy number greater than 6 or a HER-2/Chr17 ratio higher than 
2.2 was considered HER-2 positive (23). Chromosome 17 poly-
somy was defined as a centromeric chromosome 17 spot count 
of 3.0 or more in at least 80% of tumor cells (24). High-grade am-
plification was defined as a HER-2/Chr17 ratio higher than 5.0, 
and low-grade amplification was defined as a HER-2/Chr17 ra-
tio greater than 2.2 but less than 5.0 (25, 26). HER-2 gene hetero-
geneity (GH) was defined as more than 5% but less than 50% of 
the analyzed invasive tumor cells having a HER-2/Chr17 ratio 
higher than 2.2, according to CAP guidelines (27). 
Statistical analysis
Data were processed using SPSS for Windows, version 12.0 (SPSS 
Inc., Chicago, IL, USA). Student’s unpaired t-test and Fisher’s 
exact test were used to examine differences in continuous and 
categorical variables, respectively. Correlation analysis was per-
formed by Pearson’s method. Significance was assumed when 
P < 0.05. 
Ethics statement
This study was approved by the institutional review board of the 
Severance Hospital (4-2011-0015). The board exempted inform-
ed consent form.
RESULTS
Patient characteristics
Table 1 shows the clinicopathologic characteristics of the patients. 
Of 971 cases, HER-2 GH was observed in 24 (2.5%) cases, all of 
which were invasive ductal carcinoma (IDC) and showed a high-
er proportion of borderline or amplified HER-2 gene status than 
breast cancer without HER-2 GH (P < 0.001). Of 24 cases with 
HER-2 GH, all 14 cases with HER-2 amplification showed low-
grade amplification (P < 0.001). The incidence of chromosome 
17 polysomy was higher in cases with HER-2 GH than cases with-
out (P = 0.001).
Clinicopathologic features of HER-2 genetic heterogeneity 
Fig. 1 shows histology, IHC, and FISH results for breast cancer 
with HER-2 GH. Histology was IDC, not otherwise specified (NOS) 
(Fig. 1A-C). Only some invasive tumor cells (arrow) showed 3+ 
overexpression of HER-2 (Fig. 1D-F), which was compatible with 
the FISH results that showed only a proportion of invasive tumor 
cells with a HER-2/Chr17 ratio higher than 2.2 (Fig. 1G-I). Detailed 
characteristics of the 24 cases with HER-2 GH are in Table 2. HER-
2 gene AI rang-ed from 1.0 to 4.6, and the HER-2 GH pattern was 
single cell in 22 cases and cluster pattern in 2 cases. The mean 
proportion of invasive tumor cells with a HER-2/Chr17 ratio high-
er than 2.2 was 11.6% (range: 5%-25%), with significant correla-
tion between the proportion of invasive tumor cells with a HER-
2/Chr17 ratio higher than 2.2 and HER-2 AI (Fig. 2; r = 0.358 and 
P = 0.002). The proportion of invasive tumor cells with a HER-2/
Chr17 ratio higher than 2.2 increased from the no-amplification 
group to the borderline group to the amplification group, but 
the difference was not significant (Fig. 3, P = 0.085).
DISCUSSION
This study evaluated the intratumoral heterogeneity for HER-2 
in invasive breast cancer using FISH. The incidence of HER-2 GH 
was 2.4%, similar to the incidence of 1.3%–54% seen in previous 
studies (16-21). However, a simple comparison is not reasonable 
because study group characteristics, the number of study groups, 
the area evaluated by FISH, and the method of counting HER-2 
signals is likely to differ among studies. 
 HER-2 GH can be classified into geographic heterogeneity 
Table 1. Patient clinicopathologic features 
Parameters 
Total
n = 971 (%)
Non-HER-2 
GH group
n = 947 (%)
HER-2 GH 
group
n = 24 (%)
P value
Age (yr, mean ± SD) 48.9 ± 9.8 48.8 ± 9.8 50.0 ± 9.5 0.563
Histologic type
   IDC
   ILC
 
941 (96.9)
30 (3.1)
 
917 (96.8)
30 (3.2)
 
  24 (100.0)
0 (0.0)
0.376
Histologic grade
   I
   II
   III
 
110 (11.3)
633 (65.2)
228 (23.5)
 
110 (11.6)
618 (65.3)
219 (23.1)
 
0 (0.0)
15 (62.5)
  9 (37.5)
0.087
Lymph node metastasis 360 (37.1) 350 (36.9) 10 (41.7) 0.637
Estrogen receptor
   Positive
   Negative
 
632 (65.1)
339 (34.9)
 
619 (65.4)
328 (34.6)
 
13 (54.2)
11 (45.8)
0.256
Progesterone receptor
   Positive
   Negative
 
544 (56.0)
427 (44.0)
 
531 (56.1)
416 (43.9)
 
13 (54.2)
11 (45.8)
0.853
HER-2 (IHC)
   0
   1+
   2+
   3+
 
123 (12.7)
157 (16.2)
475 (48.9)
216 (22.2)
 
122 (12.9)
153 (16.1)
465 (49.1)
207 (21.9)
 
1 (4.2)
  4 (16.7)
10 (41.7)
  9 (37.5)
0.236
HER-2 (FISH)
   No amplification
   Borderline 
   Amplification 
 
662 (68.2)
15 (1.5)
294 (30.3)
 
654 (69.1)
13 (1.4)
280 (29.6)
 
  8 (33.3)
2 (8.4)
14 (58.3)
0.000
Amplification type
   Low-grade
   High-grade
 
138 (14.2)
155 (16.0)
 
124 (13.1)
155 (16.4)
 
14 (58.3)
0 (0.0)
0.000
Chromosome 17 polysomy
   Yes 
   No 
 
12 (1.2)
956 (98.8)
 
10 (1.1)
937 (98.9)
 
2 (8.3)
22 (91.7)
0.001
GH, genetic heterogeneity; IDC, invasive ductal carcinoma; ILC, invasive lobular carci-
noma; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
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and intercellular heterogeneity according to the method used 
to determine the tumor area evaluated by FISH. Geographic 
heterogeneity is defined as one core showing HER-2 amplifica-
tion, while another shows no HER-2 amplification, when multi-
ple tumor areas are sampled by tissue core using tissue microar-
ray. Previous studies using this tissue microarray method showed 
a HER-2 GH incidences of 13%-16% (19, 21). Intercellular hetero-
geneity is indicated when a different HER-2 gene status is noted 
among invasive tumor cells evaluated in one field or focus, spe-
cifically when one microscopic field has both tumor cells with a 
HER-2/Chr17 ratio that is higher than 2.2 and tumor cells have 
a lower ratio. 
 In this study, image files obtained from FISH study were retro-
spectively reviewed, and intercellular heterogeneity rather than 
geographic heterogeneity was identified. A possible explanation 
for the lower incidence of HER-2 GH in this study could be the 
study method. However, we did identify HER-2 GH, even though 
a retrospective study design was used to examine image data 
from daily clinical practice. In general, breast cancer GH results 
from clonal diversification and differences in genetic composi-
tion from growing genetic instability in some part of the tumor 
(14, 28, 29). Genetic differences in a single tumor were shown 
by laser microdissection and a comparative genomic hybridiza-
tion study, and these differences were confirmed by FISH and 
microsatellite instability analysis (15). Szollosi et al. (30) report-
ed the cell-to-cell heterogeneity of HER-2 gene amplification in 
a FISH study of breast cancer, showing prominent heterogene-
ity in both the copy number of HER-2/cell and the p185HER-2 pro-
tein level, consistent with results of this study. HER-2 GH could 
be explained by acquisition or loss of the HER-2 gene, but HER-
2 gene amplification is more plausible, considering that HER-2 
is associated with tumor aggressiveness (20). 
 Clinically, HER-2 GH is important in the interpretation of HER-
2 gene status according to FISH results and in the selection of 
patients for trastuzumab treatment. In this study, when HER-2 
gene status was interpreted by ASCO/CAP guidelines, HER-2 
GH was noted in all groups: no amplification, borderline ampli-
fication, and amplification. In addition, all cases with both HER-
Fig. 1. Breast cancer with HER-2 gene heterogeneity. The histology of breast cancer with HER-2 gene heterogeneity is invasive ductal carcinoma (H&E, × 100, A-C). Immuno-
histochemical stain for HER-2 shows heterogeneous 3+ overexpression (arrows, HER-2, × 200, D-F). Fluorescence in situ hybridization study shows heterogeneous invasive tu-
mor cells with a HER-2/Chr17 ratio higher than 2.2 (arrow, × 1,000, G-I ).
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2 GH and HER-2 amplification showed low-grade amplification. 
Therefore, HER-2 GH may affect the interpretation of HER-2 am-
plification status results by FISH. To prevent this bias, ASCO/CAP 
guidelines suggest investigating at least two (and up to four) rep-
resentative fields, which should be determined by scanning the 
entire slide (23). However, differences in the area evaluated by 
FISH and HER-2 signal counting method could give rise to in-
consistencies in interpreting HER-2 gene status results. A previ-
ous study reported that the results of routine assessment of the 
HER-2 gene might be affected by breast cancer GH with low-
grade amplification due to subclones of tumor cells with chro-
mosome 17 polysomy without gene amplification (21). Another 
important issue in HER-2 GH is trastuzumab treatment, but 
whether trastuzumab treatment is potentially beneficial to pa-
tients with HER-2 GH is not known, so clinical studies are nec-
Table 2. Characteristics of invasive breast cancer with HER-2 GH
Number
Histologic
grade
Estrogen  
receptor
Progesterone  
receptor
HER-2 
(IHC)
Amplification
index of HER-2 
HER-2  
amplification status
Proportion of  
HER-2 amplified 
cells (%)
HER-2 GH 
pattern
Chromosome 
17 polysomy
 1 2 Positive Positive 0 1.0 No  8 Single No
 2 3 Negative Positive 3+ 3.7 Low-grade  8 Single No
 3 3 Negative Negative 3+ 2.5 Low-grade  9 Single No
 4 2 Positive Positive 1+ 2.1 Borderline  8 Single No
 5 2 Negative Negative 3+ 4.1 Low-grade 20 Single No
 6 2 Positive Positive 3+ 3.0 Low-grade 18 Single No
 7 3 Negative Negative 2+ 1.0 No  8 Single No
 8 2 Positive Positive 1+ 3.0 Low-grade  8 Single No
 9 2 Positive Negative 2+ 1.9 Borderline 15 Clusters Yes
10 2 Positive Positive 2+ 1.0 No  7 Single No
11 3 Positive Positive 3+ 3.3 Low-grade 15 Single No
12 3 Positive Positive 3+ 4.5 Low-grade 15 Single No
13 2 Positive Positive 3+ 3.4 Low-grade 12 Single No
14 2 Positive Positive 3+ 3.5 Low-grade 25 Single No
15 3 Negative Negative 2+ 1.0 No 16 Single No
16 3 Negative Negative 2+ 2.5 Low-grade 10 Single No
17 2 Negative Negative 2+ 2.5 Low-grade  8 Single No
18 3 Negative Positive 2+ 1.0 No 10 Single No
19 2 Negative Negative 2+ 2.5 Low-grade 13 Single No
20 2 Negative Negative 1+ 1.0 No  6 Single No
21 2 Negative Negative 3+ 4.6 Low-grade 19 Clusters No
22 3 Positive Negative 2+ 2.7 Low-grade  8 Single No
23 2 Positive Positive 2+ 1.0 No  5 Single Yes
24 2 Positive Positive 1+ 1.0 No  7 Single No
Fig. 2. Correlation between proportion of invasive tumor cells with a HER-2/Chr17 ra-
tio higher than 2.2 and HER-2 amplification index.
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essary. Although the clinical implications of HER-2 GH for trastu-
zumab treatment are uncertain, when HER-2 GH is identified, 
the phrase “HER-2 genetic heterogeneity is present” should be 
inserted in the pathology report with: 1) percentage of invasive 
tumor cells with HER-2 amplification; 2) pattern of amplified 
cells, for example scattered cells or specific clusters; and 3) pat-
tern of specific clusters, ratio and number of chromosome enu-
meration probe 17 signals/cell or area and HER-2 signals/cell 
or area (27). In conclusion, the phenomenon of HER-2 GH in 
invasive breast cancer is identified in routine FISH examination, 
and HER-2 GH may affect the interpretation of HER-2 gene sta-
tus by FISH.
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HER-2 gene is the important biomarker for targeted immunotherapy, and the interpretation of HER-2 gene status could be 
affected by intratumoral HER-2 gene heterogeneity. In this study, we investigated intratumoral HER-2 gene heterogeneity in 
invasive breast cancer. The phenomenon of HER-2 gene heterogeneity was identified in routine FISH examination of invasive 
breast cancer. Further clinical studies are requested to evaluate the effectiveness of targeted immunotherapy for the patients with 
HER-2 gene heterogeneity.
